General Information of Drug Transporter (DT)
DT ID DTD0002 Transporter Info
Gene Name ABCC2
Protein Name Multidrug resistance-associated protein 2
Gene ID
1244
UniProt ID
Q92887
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism rs113646094
Site of GPD chr10:99804255 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>G / C>T
Minor Allele Frequency G=0.0032/16 (Global)
Genotype CG
Pravastatin Drug Info Healthy Individuals Correlated with the increased drug clearance in healthy individuals (compare with genotype CC) [1]
Pravastatin Drug Info Hypercholesterolemia Correlated with the increased expression of ABCC2 mRnA in human liver samples (compare with genotype CC) [1]
Genetic Polymorphism rs12762549
Site of GPD chr10:99861014 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>G / C>T
Minor Allele Frequency G=0.4806/2407 (Global)
Genotype CC
Docetaxel Drug Info Neoplasm Irrelevant to the neutropenia in patients (compare with genotypes CG + GG) [2]
Genotypes CG + GG
Docetaxel Drug Info Breast Neoplasm Correlated with the decreased drug clearance (compare with genotype CC) [2]
Genetic Polymorphism rs17222723
Site of GPD chr10:99836239 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP T>A
Minor Allele Frequency A=0.0373/187 (Global)
Allele A
Tenofovir Drug Info HIV Infection Correlated with the decreased renal proximal tubulopathy risk in patients (compare with Allele T); Irrelevant to the increased kidney tubular dysfunction risk in patients (compare with Allele T) [3], [4]
Doxorubicin Drug Info Non-Hodgkin Lymphoma Correlated with the increased cardiotoxicity risk in patients (compare with Allele T) [5]
Genetic Polymorphism rs2273697
Site of GPD chr10:99804058 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP G>A
Minor Allele Frequency A=0.1865/934 (Global)
Allele A
Mycophenolic acid Drug Info Kidney Transplantation Correlated with the decreased drug exposure in patients (compare with allele G) [6]
Tenofovir Drug Info HIV Infection Correlated with the increased renal proximal tubulopathy risk in patients (compare with allele G); Irrelevant to the increased fanconi syndrome risk in patients (compare with Allele G); Irrelevant to the increased kidney tubular dysfunction risk in patients (compare with Allele G); Irrelevant to the likelihood of kidney diseases in patients (compare with Allele G) [3], [4], [7], [8]
Methotrexate Drug Info Rheumatoid Arthritis Irrelevant to the drug discontinuation in patients (compare with allele G) [11]
Carbamazepine Drug Info Epilepsy Irrelevant to the number of seizures per year in patients (compare with Allele G) [12]
Oxcarbazepine Drug Info Epilepsy Irrelevant to the number of seizures per year in patients (compare with Allele G) [12]
Antiepileptics N.A. Epilepsy Correlated with the increased probability of drug response in patients (compare with allele G); Irrelevant to the drug resistance in patients (compare with Allele G); Irrelevant to the drug resistance in patients (compare with Allele G); Irrelevant to the number of seizures per year in patients (compare with Allele G) [12], [13], [14], [15]
Allele G
Mycophenolic acid Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with allele A) [14]
Carbamazepine Drug Info Epilepsy Irrelevant to the increased drug resistance in patients (compare with allele A) [15]
Oxcarbazepine Drug Info Epilepsy Irrelevant to the increased drug resistance in patients (compare with allele A) [15]
Antiepileptics N.A. Epilepsy Irrelevant to the increased drug resistance in patients (compare with allele A) [15]
Genotype AA
Methotrexate Drug Info Rheumatoid Arthritis Correlated with the increased likelihood of drug toxicity in patients (compare with genotypes AG + GG) [16]
Genotype AG
Mycophenolic acid Drug Info Lung Transplantation Correlated with the increased drug concentrations in patients (compare with genotype GG) [17]
Carbamazepine Drug Info Epilepsy Correlated with the relationship with drug resistance in patients (compare with genotype GG) [18]
Oxcarbazepine Drug Info Epilepsy Correlated with the relationship with drug resistance in patients (compare with genotype GG) [18]
Exjade N.A. Beta-Thalassemia Correlated with the increased drug concentrations in patients (compare with genotype GG) [19]
Genotype GG
Fluorouracil Drug Info Breast Neoplasm Correlated with the increased anemia risk in patients (compare with genotypes AA + AG) [20]
Doxorubicin Drug Info Breast Neoplasm Correlated with the increased anemia risk in patients (compare with genotypes AA + AG) [20]
Cyclophosphamide Drug Info Breast Neoplasm Correlated with the increased anemia risk in patients (compare with genotypes AA + AG) [20]
Mycophenolic acid Drug Info Kidney Transplantation Irrelevant to the any pharmacokinetic parameters measured in the study in patients (compare with genotype AA) [21]
Genotypes AA + AG
Irinotecan Drug Info Colorectal Neoplasm Correlated with the increased drug metabolism in patients (compare with genotype GG) [22]
Carbamazepine Drug Info Epilepsy Correlated with the increased neurological ADR risk in patients (compare with genotype GG); Irrelevant to the drug response in patients (compare with genotype GG) [23], [24]
Cisplatin Drug Info Mesothelioma Correlated with the increased overall survival and progression-free survival in patients (compare with genotype GG) [25]
Pemetrexed Drug Info Mesothelioma Correlated with the increased overall survival and progression-free survival in patients (compare with genotype GG) [25]
Tenofovir Drug Info HIV Infection Irrelevant to the glomerular disease in patients (compare with genotype GG) [26]
Antiepileptics N.A. Epilepsy Irrelevant to the increased drug resistance in patients (compare with genotype GG) [10]
Genetic Polymorphism rs3740065
Site of GPD chr10:99845936 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP A>G
Minor Allele Frequency G=0.2011/1007 (Global)
Genotype AA
Tamoxifen Drug Info Breast Neoplasm Correlated with the increased recurrence of breast cancer risk in patients (compare with genotype GG) [27]
Genotype AG
Tamoxifen Drug Info Breast Neoplasm Irrelevant to the disease recurrence risk in patients (compare with genotype AA) [28]
Genotypes AG + GG
Methotrexate Drug Info Acute B-Cell Leukemia Correlated with the increased drug plasma level in patients (compare with genotype AA); Correlated with the increased toxicity risk in patients (compare with genotype AA) [29]
Genetic Polymorphism rs3740066
Site of GPD chr10:99844450 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>G / C>T
Minor Allele Frequency T=0.2881/1443 (Global)
Allele C
Mycophenolic acid Drug Info Kidney Transplantation Irrelevant to the drug metabolism in patients (compare with Allele T) [14]
Antiepileptics N.A. Epilepsy Irrelevant to the drug resistance in patients (compare with Allele T) [11]
Allele T
Tacrolimus Drug Info Kidney Transplantation Irrelevant to the drug trough concentration in patients (compare with allele C) [30]
Antiepileptics N.A. Epilepsy Irrelevant to the number of seizures per year in patients (compare with allele C) [10]
Genotype CC
Irinotecan Drug Info Non-Small-Cell Lung Carcinoma Correlated with the increased diarrhea risk in patients (compare with Genotypes CT + TT); Irrelevant to the neutropenia in patients (compare with Genotypes CT + TT) [31]
Mycophenolic acid Drug Info Organ Transplantation Irrelevant to the any pharmacokinetic parameters measured in the study (compare with Genotype TT) [21]
Genotype CT
Mycophenolic acid Drug Info Lung Transplantation Correlated with the decreased drug concentrations in patients (compare with genotypes CC + tt) [17]
Genotype TT
Fluorouracil Drug Info Breast Neoplasm Correlated with the increased neutropenia risk in patients (compare with genotypes CC + CT) [20]
Doxorubicin Drug Info Breast Neoplasm Correlated with the increased neutropenia risk in patients (compare with genotypes CC + CT) [20]
Cyclophosphamide Drug Info Breast Neoplasm Correlated with the increased neutropenia risk in patients (compare with genotypes CC + CT) [20]
Carbamazepine Drug Info Epilepsy Irrelevant to the drug resistance in patients (compare with genotype CC) [18]
Oxcarbazepine Drug Info Epilepsy Irrelevant to the drug resistance in patients (compare with genotype CC) [18]
Genotypes CT + TT
Tacrolimus Drug Info Kidney Transplantation Correlated with the decreased drug dose in patients (compare with genotype CC); Correlated with the increased drug dose-adjusted trough concentrations in patients (compare with genotype CC) [32]
Carbamazepine Drug Info Epilepsy Correlated with the decreased drug metabolism in patients (compare with genotype CC) [33]
Fluorouracil Drug Info Breast Neoplasm Correlated with the increased nausea risk in patients (compare with genotype CC) [20]
Doxorubicin Drug Info Breast Neoplasm Correlated with the increased nausea risk in patients (compare with genotype CC) [20]
Cyclophosphamide Drug Info Breast Neoplasm Correlated with the increased nausea risk in patients (compare with genotype CC) [20]
Antiepileptics N.A. Epilepsy Correlated with the increased drug resistance in patients (compare with genotype CC); Irrelevant to the increased drug resistance in patients (compare with genotype CC) [10], [15]
Genetic Polymorphism rs717620
Site of GPD chr10:99782821 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>T
Minor Allele Frequency T=0.1350/676 (Global)
Allele C
Methotrexate Drug Info Leukemia Irrelevant to the nephrotoxicity risk in patients (compare with Allele T); Irrelevant to the prolonged high drug concentrations risk patients (compare with Allele T) [34]
Antiepileptics N.A. Epilepsy Irrelevant to the drug resistance in patients (compare with Allele T) [12]
Allele T
Methotrexate Drug Info Precursor Cell Lymphoblastic Leukemia-Lymphoma Correlated with the decreased drug clearance in patients (compare with Allele C); Correlated with the increased drug toxicity risk in patients (compare with Allele C ) [35]
Mycophenolic acid Drug Info Kidney Transplantation Correlated with the drug exposure in patients (compare with allele C) [6]
Lopinavir Drug Info HIV Infection Correlated with the increased drug toxicity risk (compare with Genotype CC) [37]
Ritonavir Drug Info HIV Infection Correlated with the increased drug toxicity risk (compare with Genotype CC) [37]
Tenofovir Drug Info HIV Infection Correlated with the increased drug toxicity risk (compare with Genotype CC); Irrelevant to the likelihood of kidney diseases in patients (compare with allele C) [8], [37]
Atazanavir Drug Info HIV Infection Correlated with the increased drug toxicity risk (compare with Genotype CC) [37]
Antiepileptics N.A. Epilepsy Irrelevant to the number of seizures per year in patients (compare with allele C) [10]
Genotype CC
Fluorouracil Drug Info Colonic Neoplasm Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT) [37]
Leucovorin Drug Info Colonic Neoplasm Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT) [37]
Oxaliplatin Drug Info Colonic Neoplasm Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT) [37]
Sorafenib Drug Info Renal Cell Carcinoma Correlated with the increased exanthema risk in patients (compare with genotype Ct) [38]
Tenofovir Drug Info HIV Infection Correlated with the increased kidney tubular dysfunction risk in patients (compare with Genotypes CT + TT); Irrelevant to the increased renal proximal tubulopathy risk in patients (compare with Genotypes CT + TT) [3], [4]
Genotype CT
Tamoxifen Drug Info Breast Neoplasm Correlated with the increased drug response in patients (compare with genotype CC) [39]
Genotype TT
Erythromycin Drug Info Bacterial Infections Correlated with the increased drug metabolism (compare with genotypes CC + CT) [40]
Fluorouracil Drug Info Colorectal Neoplasm Correlated with the increased severity of neurotoxicity syndromes in patients (compare with genotypes CC + CT) [41]
Leucovorin Drug Info Colorectal Neoplasm Correlated with the increased severity of neurotoxicity syndromes in patients (compare with genotypes CC + CT) [41]
Oxaliplatin Drug Info Colorectal Neoplasm Correlated with the increased severity of neurotoxicity syndromes in patients (compare with genotypes CC + CT) [41]
Efavirenz Drug Info HIV Infection Correlated with the increased drug concentrations in patients (compare with genotypes CC + CT) [42]
Genotypes CT + TT
Atorvastatin Drug Info Hypercholesterolemia Correlated with the decreased drug response in patients (compare with genotype CC) [43]
Methotrexate Drug Info Lymphoid Correlated with the increased drug clearance in patients (compare with genotype CC) [44]
Leucovorin Drug Info Leukemia Correlated with the increased drug distribution volume in patients (compare with genotype CC) [44]
Carbamazepine Drug Info Epilepsy Irrelevant to the drug response in patients (compare with genotype CC) [23]
Tenofovir Drug Info HIV Infection Irrelevant to the glomerular disease in patients (compare with genotype CC) [26]
Antiepileptics N.A. Epilepsy Correlated with the increased drug resistance in patients (compare with genotype CC); Irrelevant to the increased drug resistance in patients (compare with genotype CC) [10], [15], [49]
Genetic Polymorphism rs7917432
Site of GPD chr10:68399112 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP T>C
Minor Allele Frequency C=0.3087/1546 (Global)
Genotype CT
Tenofovir Drug Info HIV Infection Correlated with the decreased drug clearance in patients (compare with genotype CC) [7]
Genetic Polymorphism rs8187707
Site of GPD chr10:99850776 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP C>T
Minor Allele Frequency T=0.0310/155 (Global)
Allele T
Tenofovir Drug Info HIV Infection Correlated with the decreased drug clearance in patients (compare with genotype CC) [7]
Genetic Polymorphism rs8187710
Site of GPD chr10:99851537 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP G>A
Minor Allele Frequency A=0.0679/340 (Global)
Allele A
Lopinavir Drug Info HIV Infection Correlated with the higher drug accumulation in patients (compare with genotype GG) [46]
Doxorubicin Drug Info Non-Hodgkin Lymphoma Correlated with the increased cardiotoxicity risk in patients (compare with allele G) [5]
Genetic Polymorphism rs4148386
Site of GPD chr10:99788711 (GRCh38.p12)
GPD Type SNP
Allele(s) in dbSNP G>A
Minor Allele Frequency G=0.3886/1946 (Global)
Genotypes AA + AG
Carbamazepine Drug Info Epilepsy Correlated with the increased drug clearance in patients (compare with genotype GG) [33]
References
1 Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. 2006 Nov;16(11):801-8.
2 The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan;23(1):29-33.
3 Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006 Dec 1;194(11):1481-91.
4 Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009 Jun 1;48(11):e108-16.
5 NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005 Dec 13;112(24):3754-62.
6 Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions. Eur J Clin Pharmacol. 2017 Sep;73(9):1129-1140.
7 A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics. 2015 Feb;25(2):82-92.
8 A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection. PLoS One. 2016 Jan 25;11(1):e0147724.
9 Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
10 Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics. 2012 Jan;13(2):185-90.
11 Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011 Mar;12(3):319-25.
12 Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. Coll Antropol. 2013 Mar;37(1):41-5.
13 Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics. 2011 Oct;21(10):624-30.
14 Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. Eur J Clin Pharmacol. 2014 Oct;70(10):1211-9.
15 ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci Ther. 2012 Aug;18(8):647-51.
16 Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):572-9.
17 Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. Int J Mol Sci. 2015 Aug 25;16(9):20168-82.
18 Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014 Jul;15(10):1323-36.
19 Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J. 2015 Jun;15(3):263-71.
20 Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2018 Jan 10;9(10):9114-9136.
21 Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol. 2013 Feb;75(2):463-75.
22 Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull. 2008 Nov;31(11):2137-42.
23 A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine. Pharmacogenomics J. 2014 Oct;14(5):481-7.
24 A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
25 Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Sci Rep. 2017 Apr 19;7:46537.
26 Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. PLoS One. 2015 Nov 4;10(11):e0141931.
27 Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10;28(8):1287-93.
28 Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenomics Pers Med. 2013 Aug 26;6:93-8.
29 Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013 Feb;23(2):53-61.
30 Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018 Feb;19(3):175-184.
31 Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):115-20.
32 Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients. Pharmacotherapy. 2017 May;37(5):535-545.
33 Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
34 Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol. 2013 Dec;98(6):702-7.
35 Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014 Jan 3;9(1):e82681.
36 Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort. Pharmacogenet Genomics. 2015 Nov;25(11):541-7.
37 Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51.
38 Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs. 2013 Mar;24(3):310-4.
39 ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. Onco Targets Ther. 2016 Apr 12;9:2121-9.
40 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
41 A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013 Oct;13(5):403-9.
42 Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2016 Feb;47(2):117-23.
43 Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin. Basic Clin Pharmacol Toxicol. 2018 May;122(5):517-522.
44 Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J. 2013 Dec;13(6):507-13.
45 The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis. J Clin Neurosci. 2017 Mar;37:6-14.
46 Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics. 2009 Oct;10(10):1589-97.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.